Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

63.41 -0.19 (-0.29%)

Streaming Delayed Price Updated: 10:47 AM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	441,353
Open	62.90
Bid (Size)	63.35 (100)
Ask (Size)	63.46 (400)
Prev. Close	63.59
Today's Range	62.65 - 64.20
52wk Range	9.570 - 76.76
Shares Outstanding	105,736,200
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity ↗

February 20, 2026

Via Chartmill

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

Via Investor Brand Network

Performance

YTD	-6.5%	-6.5%
1 Month	-5.4%	-5.4%
3 Month	+43.3%	+43.3%
6 Month	+206.2%	+206.2%
1 Year	+236.2%	+236.2%

More News

The Great Rotation: How the 'One Big Beautiful Bill Act' is Igniting a Small-Cap Renaissance

February 11, 2026

Via MarketMinute

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reports Profitable Quarter on Strong Drug Launch ↗

February 05, 2026

Via Chartmill

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

From BioMedWire

Via GlobeNewswire

Arrowhead (ARWR) Q1 2026 Earnings Call Transcript ↗

February 06, 2026

Via The Motley Fool

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

February 05, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Ciena’s AI-Driven Return: Networking Giant to Join S&P 500 Benchmark

February 05, 2026

Via MarketMinute

Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million ↗

February 03, 2026

Via The Motley Fool

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

January 27, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

January 20, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? ↗

January 10, 2026

Via The Motley Fool

Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value

January 08, 2026

Via MarketMinute

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

January 07, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

January 07, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

January 06, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble

January 06, 2026

Via MarketMinute

Why Did ARWR Stock Surge Over 15% Pre-Market Today? ↗

January 06, 2026

Via Stocktwits

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

January 06, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

January 05, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

December 23, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Via MarketMinute

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 15, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

December 08, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

December 02, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?

Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market

What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 63.41

When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 02/23/26 10:47 AM ET

What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 6.70B

How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?

Arrowhead Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.